Granulomatosis with Polyangiitis
-
Subject Areas on Research
-
A brief history of Wegener's granulomatosis: on limited, localized, and generalized forms of the disease: comment on the article by the Wegener's Granulomatosis Etanercept Trial Research Group.
-
A case of restrictive strabismus secondary to orbital Wegener's granulomatosis.
-
A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS).
-
A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis.
-
A prospective study of antineutrophil cytoplasmic antibody (c-ANCA) and clinical criteria in diagnosing Wegener's granulomatosis.
-
A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis.
-
ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis.
-
Allosteric modulation of proteinase 3 activity by anti-neutrophil cytoplasmic antibodies in granulomatosis with polyangiitis.
-
Alpha₁-antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis.
-
Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestations.
-
Antiphospholipid antibodies in patients with Wegener's granulomatosis and polyarteritis nodosa.
-
Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis.
-
Assessing the performance of the Birmingham Vasculitis Activity Score at diagnosis for children with antineutrophil cytoplasmic antibody-associated vasculitis in A Registry for Childhood Vasculitis (ARChiVe).
-
Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's).
-
Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosis.
-
Association of Wegener's granulomatosis with HLA-B8.
-
Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis.
-
Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
-
Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study.
-
Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood.
-
Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.
-
Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
-
Cocaine-induced pseudovasculitis.
-
Comparing Presenting Clinical Features in 48 Children With Microscopic Polyangiitis to 183 Children Who Have Granulomatosis With Polyangiitis (Wegener's): An ARChiVe Cohort Study.
-
Computer assisted tomography of orbital lesions in Wegener's granulomatosis.
-
Cyclophosphamide treatment of diabetes insipidus in Wegener's granulomatosis.
-
Cyclosporin A therapy for Wegener's granulomatosis.
-
Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).
-
Diabetes insipidus associated with Wegener's granulomatosis successfully treated with cyclophosphamide.
-
Diagnosis and treatment of the systemic and cutaneous necrotizing vasculitis syndromes.
-
Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis.
-
Etanercept plus standard therapy for Wegener's granulomatosis.
-
Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis.
-
Granulomatous choroiditis in Wegener granulomatosis.
-
Herpes zoster in immunocompromised patients: incidence, timing, and risk factors.
-
Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.
-
IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis.
-
Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis.
-
Increased sensitivity of the European medicines agency algorithm for classification of childhood granulomatosis with polyangiitis.
-
Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis.
-
Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis.
-
Multiple unusual manifestations of Wegener's granulomatosis: breast mass, microangiopathic hemolytic anemia, consumptive coagulopathy, and low erythrocyte sedimentation rate.
-
Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets.
-
Orbital granulomatosis with polyangiitis (Wegener granulomatosis): clinical and pathologic findings.
-
Orbital involvement by Wegener's granulomatosis: imaging findings.
-
Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
-
Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's).
-
Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis.
-
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
-
Sequence-Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in ADA2.
-
Single-center experience with renal transplantation in patients with Wegener's granulomatosis.
-
Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort.
-
Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.
-
The Role of T Helper Type 2 (Th2) Cytokines in the Pathogenesis of Eosinophilic Granulomatosis with Polyangiitis (eGPA): an Illustrative Case and Discussion.
-
The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event.
-
The ocular manifestations of Wegener's granulomatosis. Fifteen years experience and review of the literature.
-
The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis.
-
The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations.
-
Wegener granulomatosis: CT and MR findings.
-
Wegener's granulomatosis involving the breast. Report of three cases and review of the literature.
-
Wegener's granulomatosis of the uterine cervix: a case report and review of the literature.
-
Wegener's granulomatosis with cardiac involvement masquerading as Lyme disease.
-
Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years.
-
Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s.
-
Keywords of People